secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aridis Pharmaceuticals, Inc. (—)
CIK:        0001614067
Form:       8-K
Filed at:   2023-05-25T23:59:59+00:00
Accession:  0001493152-23-019112
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01, 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aridis receives Nasdaq delisting notice for late Q1 filing; auditor Baker Tilly resigns
--------------------------------------------------------------------------------

- Nasdaq notified Aridis of additional delisting basis for failure to file Q1 2023 Form 10-Q; Hearings Panel to consider.
- Baker Tilly US, LLP resigned as independent auditor effective after filing of Q1 10-Q; company interviewing replacements.
- No accounting disagreements with Baker Tilly; material weakness in internal controls was previously disclosed in 2022 10-K.
- Aridis has presented its views to Nasdaq Panel regarding continued listing on the Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1614067/000149315223019112/0001493152-23-019112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1614067/000149315223019112/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-019112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer